MannKind Corporation (Nasdaq: MNKD), a biopharmaceutical company focused on developing innovative, patient-centric therapies for chronic diseases, and Rose Pharma Inc. (Rose Pharma) today announced that they have entered into a worldwide licensing and collaboration agreement to develop ROSE-010 Technosphere for weight management. ROSE-010 is an investigational, rapid-acting glucagon-like peptide-1 (GLP-1) receptor agonist that will be formulated using MannKind’s proprietary Technosphere dry-powder inhalation technology.
9/9/2026
Royalty Pharma plc (Nasdaq: RPRX) today announced an update on Novartis’ Phase 3 results from the HORIZON outcomes trial for pelacarsen, an antisense oligonucleotide studied in patients with atherosclerotic cardiovascular (CV) disease and elevated lipoprotein(a), or Lp(a).
9/4/2026
Royalty Pharma plc (Nasdaq: RPRX) today announced an agreement for $100 million in funding to Zealand Pharma in exchange for Zealand Pharma’s economics related to rusfertide (PTG-300), a potential first-in-class therapy for polycythemia vera, a rare and chronic blood disorder.
8/12/2026
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced the completion of enrollment in the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy of ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with the bispecific antibody glofitamab (COLUMVI®) in patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (r/r DLBCL).
6/30/2026
Cristcot, a clinical-stage pharmaceutical company advancing targeted therapies for gastrointestinal diseases, today announced that the Company presented its poster with a select oral presentation assessing HPA integrity at the Endocrine Society’s ENDO 2026 Conference on June 14, 2026, in Chicago, Illinois. The ENDO Conference brings together leading clinicians, researchers, and industry experts with a focus on emerging therapies and innovation.
6/27/2026
The collaboration marks an important step in VERIGRAFT’s preparations for future clinical development activities in the United States and supports the company’s broader strategy to advance P-TEV, its personalized tissue-engineered vein.
6/24/2026
Cibus, Inc. (Nasdaq: CBUS) today welcomed a landmark decision by the European Union. For the first time, crops improved without adding foreign DNA will be treated like conventionally bred crops, not like transgenic GMOs.
6/17/2026
Kyntra Bio (Nasdaq: KYNB) today announced additional data from the Phase 3 MATTERHORN trial showing improvements in transfusion independence in patients with anemia associated with lower-risk myelodysplastic syndromes (LR-MDS) treated with roxadustat will be presented as a poster at the European Hematology Association (EHA) Congress 2026, taking place June 11-14, 2026 in Stockholm, Sweden.
6/11/2026
Cibus, Inc. (Nasdaq: CBUS) (the “Company” or “Cibus”), a leading agricultural technology company that develops and licenses plant traits to seed companies, today announced key leadership changes pursuant to the Company’s previously announced succession planning strategy. As part of this plan, Craig Wichner, a board member since November 2025, has been appointed as the Company’s Chief Executive Officer.
6/8/2026
VERIGRAFT, a Swedish clinical-stage biotechnology company developing personalized, fully biological therapies, and TFS HealthScience, a full-service global contract research organization (CRO), today announced their collaboration on the pivotal Phase II/III trial of VERIGRAFT’s P-TEV (personalized tissue-engineered vein) in patients with chronic venous insufficiency (CVI).
5/28/2026
VERIGRAFT has received Clinical Trial Application (CTA) approval for its Phase II/III study evaluating P-TEV in patients with chronic venous insufficiency (CVI).
5/13/2026
Cristcot, a clinical-stage pharmaceutical company advancing targeted therapies for gastrointestinal diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s New Drug Application (NDA) under section 505(b)(2) of the Federal Food, Drug and Cosmetic Act for its next-generation hydrocortisone acetate (ngHCA) 90-milligram suppository administered using Cristcot’s patented, FDA-approved Sephure® suppository applicator. The FDA has set a PDUFA target date in October 2026. If approved, ngHCA would be the first and only FDA-approved hydrocortisone acetate (HCA) suppository.
4/21/2026
VERIGRAFT has completed its first clinical trial with P-TEV — a personalized tissue therapy for patients with severe chronic venous insufficiency (CVI). The P-TEV clinical trial results mark a major step forward in the clinical development of personalized tissue therapies for vascular disease. The study took place in Spain and represents the first time VERIGRAFT’s technology has been tested in humans.
10/29/2025
VIRGINIA BEACH, Va. — October 24, 2025 — Rose Pharma Inc., a clinical-stage biopharmaceutical company developing ROSE-010, a rapid-onset, short-duration GLP-1 therapy targeting both weight management and acute IBS pain, today announced that Chief Executive Officer Enda Kenny, PhD will present data from its recent clinical trial in weight management at ObesityWeek® 2025 (sponsored by The Obesity Society) on Tuesday, November 4, 2025 at 7:30 p.m. ET in Atlanta, GA.
10/27/2025
Rose Pharma Featured in The Obesity Bulletin - Rose Pharma Unveils Rose-010: First GLP-1 Therapy Focused on Weight Loss Maintenance
5/16/2025
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced data presentations from the LOTIS-7 Phase 1b clinical trial evaluating ZYNLONTA (loncastuximab tesirine-lpyl) in combination with glofitamab in patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL).
5/14/2025
Royalty Pharma plc (Nasdaq: RPRX) today announced two major steps to enhance shareholder value.
1/10/2025
Cristcot, a clinical-stage pharmaceutical company advancing innovative therapies for gastrointestinal diseases, today announced positive topline results from its pivotal Phase 3 cessa clinical trial evaluating its novel hydrocortisone acetate (HCA) suppository administered with the Sephure® suppository applicator in patients with ulcerative colitis (UC) of the rectum.
1/9/2025
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced positive initial data from the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy of ZYNLONTA® in combination with the bispecific antibody glofitamab (COLUMVI™) in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL).
12/11/2024
Cibus, Inc. (Nasdaq: CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies for royalties, and Biographica, a UK-based leader in AI and graph machine learning for gene discovery, are pleased to announce a collaborative pilot project focused on advancing disease resistance in oilseed rape and Canola.
11/19/2024
